Lower blood levels of the peptide vasostatin-2 predict coronary restenosis in patients, and the peptide prevents artery re-narrowing in mice by blocking smooth muscle cell overgrowth via the ACE2 pathway.
Lower vasostatin-2 predicts restenosis (p<0.001)Among 884 patients after coronary stenting, those whose arteries re-narrowed had significantly lower levels of this protective peptide, identifying it as both a biomarker and potential therapeutic target.
What the researchers found
Vasostatin-2, a bioactive peptide cleaved from chromogranin A, prevents artery re-narrowing after coronary stent placement. Patients with coronary restenosis had significantly lower serum vasostatin-2 levels than those without (p<0.001). In mice, recombinant vasostatin-2 inhibited neointimal hyperplasia after arterial injury by binding to ACE2, activating the NR1D1/Gas1 pathway, promoting smooth muscle cell death, and preventing their excessive proliferation. Mutant vasostatin-2 that couldn't bind ACE2 lost its protective effect.
Why it matters
Coronary stent restenosis (re-narrowing of arteries after treatment) remains a significant clinical problem affecting up to 10% of patients after coronary angioplasty. Vasostatin-2 is a naturally occurring peptide biomarker that predicts restenosis risk and may itself be therapeutic. This study identifies both a predictive biomarker and a potential treatment target for one of cardiology's persistent challenges.
The numbers in context
n=884 patients (442 with restenosis, 442 without) · lower vasostatin-2 in restenosis group (p<0.001) · inhibited neointimal hyperplasia in mice · ACE2/MasR/PPARγ/NR1D1/Gas1 pathway identified · multi-omics validation
How the study worked
The study combined clinical and preclinical approaches. Clinically, serum vasostatin-2 levels were measured in 884 patients with and without restenosis after PCI. Preclinically, recombinant vasostatin-2 or saline was administered in a mouse femoral artery injury model. Multi-omics approaches (bulk RNA sequencing, CUT&Tag, GST pull-down/mass spectrometry) characterized the mechanism. ACE2-binding incompetent vasostatin-2 mutants and NR1D1-deficient VSMCs validated the pathway.
Who was studied
884 patients after PCI (442 with restenosis, 442 without) and mouse femoral artery injury model
What this study cannot tell us
The clinical portion is observational (association, not causation). The preclinical model used femoral artery injury in mice, which differs from human coronary stent restenosis. Whether exogenous vasostatin-2 administration could prevent restenosis in humans has not been tested. The optimal dosing, route, and timing of vasostatin-2 delivery for potential therapeutic use were not established.
How to read the evidence
This study uniquely combines clinical observational data (884 patients) with preclinical mechanistic experiments (mouse model with multi-omics). The human clinical data establishes an association, while the animal experiments provide strong mechanistic evidence for causation. Together, they provide compelling translational evidence.
When this study was published
Published in 2025, this study represents recent research at the intersection of peptide biology and cardiovascular medicine.
The bigger picture
This study connects peptide biology to interventional cardiology in a novel way. Vasostatin-2 is part of the chromogranin A peptide family, which includes several bioactive fragments with cardiovascular effects. The finding that this peptide acts through ACE2 is particularly intriguing given ACE2's role in the renin-angiotensin system and its newfound prominence since COVID-19. It suggests vasostatin-2 could be developed as both a predictive biomarker and a therapeutic peptide for preventing restenosis.
Questions still open
- Could vasostatin-2-coated stents prevent restenosis more effectively than current drug-eluting stents?
- Is vasostatin-2 protective against other forms of vascular remodeling, such as atherosclerosis or post-surgical stenosis?
- What determines vasostatin-2 levels in the blood, and can they be increased through treatment?
Common questions
What is vasostatin-2 and where does it come from?
Why does this peptide work through ACE2?
Read the original research
Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.
Cardiovascular research, 121(14), 2260-2277
Citation
Chen, Qiujing; Liu, Jingmeng; Madonna, Rosalinda; Li, Feifei; Chen, Shuai; Li, Leying; Wu, Xinrui; Maimati, Yipaerguli; Ding, Fenghua; Wang, Xiaoqun; Shen, Ying; Zhang, Ruiyan; Shen, Weifeng; Dai, Yang; Lu, Lin; De Caterina, Raffaele. (2025). Vasostatin-2 attenuates injury-induced neointimal hyperplasia through the ACE2/MasR/PPARγ/NR1D1/Gas1 axis.. Cardiovascular research, 121(14), 2260-2277. https://doi.org/10.1093/cvr/cvaf192